Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of August 13, 2025 • 7:31 AM ET

Date/Time Source News Release
08/11/2025 08:45 AM EDT GlobeNewswire Oragenics Q2 2025 Shareholder Update
07/31/2025 08:30 AM EDT GlobeNewswire Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
07/16/2025 08:39 AM EDT GlobeNewswire Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
07/02/2025 04:15 PM EDT GlobeNewswire Oragenics Completes Approximately $16.5 Million Offering
07/01/2025 08:31 AM EDT GlobeNewswire Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
06/10/2025 08:30 AM EDT GlobeNewswire Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
05/28/2025 07:00 AM EDT GlobeNewswire Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
05/13/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
05/12/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
04/23/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
Page

Additional News

As of August 13, 2025 • 7:31 AM ET

Date/Time Source News Release
08/11/2025 09:35 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
07/31/2025 09:35 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
07/16/2025 10:10 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
07/03/2025 09:05 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
07/01/2025 02:30 PM EDT PRISM News PRISM Mid-Day Movers: Medicare Milestone and Energy Innovation Drive Index Gains
07/01/2025 10:14 AM EDT BioMedWire BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering
07/01/2025 08:46 AM EDT SeekingAlpha Oragenics announces $20M preferred stock offering; shares surge over 138%
06/10/2025 10:00 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) to Spotlight Concussion Candidate at BIO 2025 and Neurotrauma Symposium
06/04/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: MedDevices Index Strengthens on Expanded European Footprint for Robotic Hernia Repair
06/02/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: AI Infrastructure and Pharma Indices Jump On Lease Deal and Trial Results
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.